Profil
Mr. Thomas Ulmer is a Chief Financial Officer at PYC Therapeutics Ltd. He is on the Board of Directors at Aravax Pty Ltd. Mr. Ulmer was previously employed as a Co-Managing Director by Immatics Biotechnologies GmbH, a Head-Planning, Forecasting & Resource Allocation by Merck KGaA, a Chief Financial Officer by Cell Therapies Pty Ltd., and a Chief Financial Officer by Immatics NV.
He received his MBA from the University of Giessen.
Aktive Positionen von Thomas Ulmer
| Unternehmen | Position | Beginn |
|---|---|---|
| PYC THERAPEUTICS LIMITED | Finanzdirektor/CFO | 07.07.2026 |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Develops treatments for peanut allergies | Direktor/Vorstandsmitglied | 01.11.2020 |
Ehemalige bekannte Positionen von Thomas Ulmer
| Unternehmen | Position | Ende |
|---|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Vorstandsvorsitzender | 12.02.2020 |
| MERCK KGAA | Corporate Officer/Principal | 01.07.2016 |
Cell Therapies Pty Ltd. | Finanzdirektor/CFO | - |
| IMMATICS N.V. | Finanzdirektor/CFO | - |
Ausbildung von Thomas Ulmer
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Merck KGaA
Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
PYC Therapeutics Ltd.
PYC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Provides discovery and development of peptide based therapeutic candidates | Health Technology |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
University of Giessen
University of Giessen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cell Therapies Pty Ltd. | |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Develops treatments for peanut allergies | Health Technology |
Immatics NV
Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
















